Lupus & antiphospholipid syndrome
Systemic Lupus Erythematosus Mortality Among Decedents Aged ≥15 Years—United States, 2018–2023
Study context
- Population
- US decedents aged ≥15 years with any mention of systemic lupus erythematosus (SLE) (ICD-10 M32) on the death certificate, 2018–2023deaths with any mention of SLE
- Participants
- 14,936 decedents
- Exposure
- Females vs Males vs Non-Hispanic African American vs Other non-Hispanic racial groups vs Hispanic vs Non-Hispanic vs South vs Other regions
- Outcome
- Age-adjusted SLE mortality rate per million population (SLE as underlying or contributing cause of death)
- Follow-up
- 2018–2023
Methodological detailsdeath certificate data, CDC WONDER, age-adjusted death rates
- Death certificate data
- CDC WONDER
- Age-adjusted death rates
Main finding
As reported in the abstract
Age-adjusted SLE mortality rate per million population
Observational data: associations, not effects.
Further findings
Deaths listing SLE as the underlying cause · 2018–2023
- SLE as underlying cause
- 6,414 (42.9%)
Leading underlying causes when SLE was a contributing cause (age-adjusted rate per million)
- Heart disease
- 0.93
- Cancer
- 0.56
- COVID-19
- 0.51
Overall age-adjusted SLE mortality rate by year · 2020 and 2021
- Significantly higher in 2020 and 2021 than in all other study years (likely COVID-19 pandemic impact)
Original publication
Systemic Lupus Erythematosus Mortality Among Decedents Aged ≥15 Years—United States, 2018–2023. Arthritis Care Res (Hoboken). Published 13 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →